These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 22377768

  • 1. Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response.
    Kulkarni S, Saju L, Farver C, Tubbs R.
    Int J Cancer; 2012 Nov 15; 131(10):2420-32. PubMed ID: 22377768
    [Abstract] [Full Text] [Related]

  • 2. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.
    Breast Cancer Res Treat; 2012 Dec 15; 136(3):739-48. PubMed ID: 23117856
    [Abstract] [Full Text] [Related]

  • 3. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.
    Breast Cancer Res; 2011 Dec 15; 13(6):R121. PubMed ID: 22123186
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y, Wang Z, Jiang Y, Yang C.
    Cancer Lett; 2011 Dec 26; 313(1):54-63. PubMed ID: 21943825
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
    Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M.
    Breast Cancer Res Treat; 2013 Aug 26; 141(1):43-53. PubMed ID: 23959396
    [Abstract] [Full Text] [Related]

  • 9. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X, Xu Y, Ding Y, Li C, Zhao H, Wang J, Meng S.
    Mol Cancer; 2018 Aug 02; 17(1):113. PubMed ID: 30068375
    [Abstract] [Full Text] [Related]

  • 10. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, Guan X.
    Int J Mol Med; 2011 Dec 02; 28(6):985-91. PubMed ID: 21887460
    [Abstract] [Full Text] [Related]

  • 11. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
    Yeh ES, Abt MA, Hill EG.
    Breast Cancer Res Treat; 2015 Jan 02; 149(1):91-8. PubMed ID: 25515931
    [Abstract] [Full Text] [Related]

  • 12. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM.
    Cancer Res; 2008 Jul 15; 68(14):5878-87. PubMed ID: 18632642
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 15; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
    Huynh FC, Jones FE.
    PLoS One; 2014 Oct 15; 9(12):e114419. PubMed ID: 25532106
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM, Zhu HY, Bai WD, Wang T, Wang L, Chen Y, Yang AG, Jia LT.
    BMC Cancer; 2014 Feb 26; 14():134. PubMed ID: 24571711
    [Abstract] [Full Text] [Related]

  • 16. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.
    Mol Pharmacol; 2006 Nov 26; 70(5):1534-41. PubMed ID: 16887935
    [Abstract] [Full Text] [Related]

  • 17. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
    Nawa M, Osada S, Morimitsu K, Nonaka K, Futamura M, Kawaguchi Y, Yoshida K.
    Anticancer Res; 2012 Jan 26; 32(1):13-9. PubMed ID: 22213283
    [Abstract] [Full Text] [Related]

  • 18. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P, Di Modugno F, Circo R, Spada S, Di Benedetto A, Melchionna R, Palermo B, Matteoni S, Soddu S, Mottolese M, De Maria R, Nisticò P.
    Oncogene; 2016 Feb 18; 35(7):887-96. PubMed ID: 25961924
    [Abstract] [Full Text] [Related]

  • 19. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 18; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

  • 20. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L, Li Y, Shen E, Cao F, Li L, Li X, Wang X, Kariminia S, Chang B, Li H, Li Q.
    Int J Oncol; 2017 Nov 18; 51(5):1553-1562. PubMed ID: 29048656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.